IO Biotech to Participate in the Jefferies Healthcare Conference
IO Biotech (Nasdaq: IOBT) announces participation in the Jefferies Global Healthcare Conference scheduled for June 8-10, 2022, in New York City. CEO Mai-Britt Zocca will hold one-on-one investor meetings and present on June 8, 2022, from 8:30 to 8:55 a.m. ET. A live webcast of the presentation can be accessed through the company’s website. IO Biotech focuses on developing immune-modulating cancer therapies utilizing its T-win® technology platform. A replay of the presentation will be available for 90 days post-conference.
- None.
- None.
NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today that the Company will be participating in the Jefferies Global Healthcare Conference, to be held June 8-10, 2022, in New York City. Mai-Britt Zocca, Ph.D., President and CEO of IO Biotech will be available to meet with investors in-person on a one-on-one basis throughout the conference.
Presentation Details
Date and Time: Wednesday, June 8, 2022 at 8:30 – 8:55 a.m. ET
Presenter: Mai-Britt Zocca, President & CEO
Webcast Link: https://wsw.com/webcast/jeff240/iob/1678650
A webcast replay of the presentation will be available from the Investors section of the Company’s website at www.iobiotech.com for 90 days.
About IO Biotech
IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform. The T-win® platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. IO Biotech is advancing in clinical studies its lead immuno-oncology candidate, IO102-IO103, targeting IDO and PD-L1, and through clinical and preclinical development its other pipeline candidates. IO Biotech is headquartered in Copenhagen, Denmark and has additional offices within the United States (New York, New York and Rockville, Maryland) and United Kingdom (Monmouthshire).
For further information, please visit www.iobiotech.com
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including regarding future clinical trials, are based on IO Biotech’s current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.
Company Contact:
Mai-Britt Zocca, Ph.D.
President and CEO of IO Biotech
mz@iobiotech.com
Investor Inquiries:
Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com
Media Contact:
Raena Mina, Ph.D.
LifeSci Communications
646-606-1438
rmina@lifescicomms.com
FAQ
When will IO Biotech present at the Jefferies Global Healthcare Conference?
Who is the CEO of IO Biotech?
What is the focus of IO Biotech's research?
How can I watch the IO Biotech presentation?
What technology platform does IO Biotech use?
Where is IO Biotech headquartered?
Will the presentation be available after the conference?
